恶性黑色素瘤免疫治疗超进展研究现状

doi:10.11904/j.issn.1002-3070.2023.02.009

Abstract

Abstract: Malignant melanoma is a highly malignant solid tumor with strong invasiveness and poor prognosis.With marketing of immunotherapy drugs,the overall survival rate of malignant melanoma patients has been greatly improved.However,some patients progress rapidly and deteriorate rapidly after immunotherapy,which is called hyperprogressive disease.The survival rate of hyperprogressive patients is lower and their prognosis is worse.In order to detect and prevent the occurrence of hyperprogressionin time and reduce the mortality of patients,this article reviews the research status immunotherapy for hyperprogression of malignant melanoma.

Key words: Malignant melanoma, Immunotherapy, Hyperprogression

CLC Number:

R739.5

LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma[J]. Journal of Practical Oncology, 2023, 37(2): 144-148.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.02.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I2/144

References

1 Xue Y,Gao S,Gou J,et al.Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors:preclinical and clinical studies and mechanism of action[J].Expert Opin Drug Deliv,2021,18(2):187-203.
2 Champiat S,Dercle L,Ammari S,et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J].Clin Cancer Res,2017,23(8):1920-1928.
3 Ferrara R,Mezquita L,Texier M,et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy[J].JAMA Oncol,2018,4(11):1543-1552.
4 Gandara D,Reck M,Moro-Sibilot D,et al.Fast progression in non-small cell lung cancer:results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel[J].J Immunother Cancer,2021,9(3):e001882.
5 Mellema WW,Burgers SA,Smit EF.Tumor flare after start of RAF inhibition in KRAS mutated NSCLC:a case report[J].Lung Cancer,2015,87(2):201-203.
6 Novik AV,Protsenko SA,Baldueva IA,et al.Vemurafenib-induced progression of breast cancer:a case report and review of the literature[J].Target Oncol,2016,11(2):235-238.
7 Kanjanapan Y,Day D,Wang L,et al.Hyperprogressive disease in early-phase immunotherapy trials:clinical predictors and association with immune-related toxicities[J].Cancer,2019,125(8):1341-1349.
8 Saada-Bouzid E,Defaucheux C,Karabajakian A,et al.Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J].Ann Oncol,2017,28(7):1605-1611.
9 Kato S,Goodman A,Walavalkar V,et al.Hyperprogressors after immunotherapy:analysis of genomic alterations associated with accelerated growth rate[J].Clin Cancer Res,2017,23(15):4242-4250.
10 Matos I,Martin-Liberal J,Garcia-Ruiz A,et al.Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria[J].Clin Cancer Res,2020,26(8):1846-1855.
11 Kim CG,Kim C,Yoon SE,et al.Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J].J Hepatol,2021,74(2):350-359.
12 Kamada T,Togashi Y,Tay C,et al.PD-1(+)regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J].Proc Natl Acad Sci U S A,2019,116(20):9999-10008.
13 Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J].N Engl J Med,2015,373(1):23-34.
14 Huang RY,Francois A,McGray AR,et al.Compensatory upregulation of PD-1,LAG-3,and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer[J].Oncoimmunology,2017,6(1):e1249561.
15 Li Q,Ngo PT,Egilmez NK.Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy[J].Cancer Immunol Immunother,2021,70(6):1789-1796.
16 Lamberti G,Sisi M,Andrini E,et al.The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC):which are the involved players?[J].Cancers (Basel),2020,12(11):3129.
17 Lo Russo G,Moro M,Sommariva M,et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade[J].Clin Cancer Res,2019,25(3):989-999.
18 Bakema JE,van Egmond M.Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer[J].Curr Top Microbiol Immunol,2014,382:373-392.
19 Xiong D,Wang Y,Singavi AK,et al.Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer[J].iScience,2018,9:258-277.
20 Wartewig T,Kurgyis Z,Keppler S,et al.PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis[J].Nature,2017,552(7683):121-125.
21 Landre T,Taleb C,Nicolas P,et al.Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?[J].J Clin Oncol,2016,34(15_suppl):3070-3070.
22 Padron A,Hurez V,Gupta HB,et al.Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model[J].Exp Gerontol,2018,105:146-154.
23 Conforti F,Pala L,Bagnardi V,et al.Cancer immunotherapy efficacy and patients′sex:a systematic review and meta-analysis[J].Lancet Oncol,2018,19(6):737-746.
24 Yilmaz M,Akovali B.Hyperprogression after nivolumab for melanoma:a case report[J].J Oncol Pharm Pract,2020,26(1):244-251.
25 Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Five-year survival with combined nivolumab and ipilimumab in advanced melanoma[J].N Engl J Med,2019,381(16):1535-1546.
26 Wagner NB,Forschner A,Leiter U,et al.S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies[J].Br J Cancer,2018,119(3):339-346.
27 Sasaki A,Nakamura Y,Mishima S,et al.Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer[J].Gastric Cancer,2019,22(4):793-802.
28 Kim JY,Lee KH,Kang J,et al.Hyperprogressive disease during anti-PD-1 (PDCD1)/ PD-L1 (CD274)therapy:a systematic review and meta-analysis[J].Cancers (Basel),2019,11(11):1699.
29 石琳娜,隋红.原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J].实用肿瘤学杂志,2020,34(6):560-564.
30 Margetts J,Ogle LF,Chan SL,et al.Neutrophils:driving progression and poor prognosis in hepatocellular carcinoma?[J].Br J Cancer,2018,118(2):248-257.
31 尹蕾,杨旭东,杨悦,等.中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J].实用肿瘤学杂志,2021,35(2):117-124.
32 Forschner A,Hilke FJ,Bonzheim I,et al.MDM2,MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma[J].Cancers (Basel),2020,12(3):540.
33 Fang DD,Tang Q,Kong Y,et al.MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment[J].J Immunother Cancer,2019,7(1):327.
34 Wang X,Wang F,Zhong M,et al.The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy[J].Mol Cancer,2020,19(1):81.
35 Singavi AK,Menon S,Kilari D,et al.Predictive biomarkers for hyper-progression (HP)in response to immune checkpoint inhibitors (ICI)– analysis of somatic alterations (SAs)[J].Ann Oncol,2017,28:405.
36 Cabel L,Proudhon C,Romano E,et al.Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy[J].Nat Rev Clin Oncol,2018,15(10):639-650.
37 Nakamoto R,L CZ,Rosenberg J,et al.Imaging characteristics and diagnostic performance of 2-deoxy-2-[¹⁸F]fluoro-D-glucose PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy[J].Mol Imaging Biol,2021,23(1):139-147.
38 Ogawara D,Soda H,Iwasaki K,et al.Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy[J].Thorac Cancer,2018,9(1):175-180.

[1]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[2]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[3]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[4]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[5]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[6]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[7]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[8]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.
[9]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[10]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[11]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[12]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[13]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[14]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[15]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.

Current status of advanced research on immunotherapy for malignant melanoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments